Skip to main navigation Skip to search Skip to main content

Onvansertib plus standard-of-care chemotherapy plus bevacizumab in first-line RAS-mutated metastatic colorectal cancer (mCRC): Interim results from the phase 2 randomized CRDF-004 trial.

  • Heinz Josef Lenz
  • , Hao Xie
  • , Daniel H. Ahn
  • , David L. Bajor
  • , Adel Kardosh
  • , Alisha Heather Bent
  • , Alex Kane
  • , Ramanand Arun Subramanian
  • , Alex Dmitrienko
  • , Roger Sidhu
  • , Joel R. Hecht

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Onvansertib plus standard-of-care chemotherapy plus bevacizumab in first-line RAS-mutated metastatic colorectal cancer (mCRC): Interim results from the phase 2 randomized CRDF-004 trial.'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Immunology and Microbiology